

JUNE 16, 2021 ADDENDUM: Apple Health Preferred Drug List (AHPDL) Class Names

The drug classes listed in the agenda have been shortened to allow for easier organization of the topics. The classes listed below reflect the exact naming used by the Washington State Health Care Authority for the AHPDL.

ASTHMA AND COPD AGENTS : ANTICHOLINERGICS
ASTHMA AND COPD AGENTS : INHALED CORTICOSTEROID COMBINATIONS
ASTHMA AND COPD AGENTS : INHALED CORTICOSTEROIDS
ASTHMA AND COPD AGENTS : LONG ACTING MUSCARINIC AGENT / LONG ACTING BETA AGONIST COMBINATIONS
ASTHMA AND COPD AGENTS : LONG ACTING MUSCARINIC AGENTS
ASTHMA AND COPD AGENTS : MONOCLONAL ANTIBODIES
ASTHMA AND COPD AGENTS : PHOSPHODIESTERASE 4 INHIBITORS
HEMATOPOIETIC AGENTS : ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
HEMATOPOIETIC AGENTS : GAUCHER DISEASE
HEMATOPOIETIC AGENTS : GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)
HEMATOPOIETIC AGENTS : SICKLE CELL ANEMIA
HEMATOPOIETIC AGENTS : THROMBOPOIESIS (TPO) STIMULATING PROTEINS
IMMUNE MODULATORS : THALIDOMIDE ANALOGUES
ONCOLOGY AGENTS : ALKYLATING AGENTS - ORAL
ONCOLOGY AGENTS : ANTIMETABOLITES - ORAL
ONCOLOGY AGENTS : ANTINEOPLASTICS MISC - ORAL
ONCOLOGY AGENTS : BCL-2 INHIBITORS - ORAL
ONCOLOGY AGENTS : HISTONE DEACETYLASE INHIBITORS - ORAL
ONCOLOGY AGENTS : ISOCITRATE DEHYDROGENASE-1 (IDH1) INHIBITORS - ORAL
ONCOLOGY AGENTS : ISOCITRATE DEHYDROGENASE-2 (IDH2) INHIBITORS - ORAL
ONCOLOGY AGENTS : JANUS ASSOCIATED KINASE (JAK) INHIBITORS - ORAL
ONCOLOGY AGENTS : PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS - ORAL
ONCOLOGY AGENTS : PROTEASOME INHIBITORS - ORAL
ONCOLOGY AGENTS : XPO1 INHIBITORS - ORAL